Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924516 | PMC |
| http://dx.doi.org/10.1038/npp.2013.272 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world analysis of acamprosate use in patients with cirrhosis and alcohol-associated hepatitis.
BMJ Open Gastroenterol
December 2024
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Objective: Preventing return to alcohol is of critical importance for patients with alcohol-related cirrhosis and/or alcohol-associated hepatitis. Acamprosate is a widely used treatment for alcohol use disorder (AUD). We assessed the impact of acamprosate prescription in patients with advanced liver disease on abstinence rates and clinical outcomes.
View Article and Find Full Text PDFModern pharmacotherapy guidance for treating alcohol use disorders.
Expert Opin Pharmacother
December 2024
Forel Clinic, Addiction Treatment Center, Switzerland.
Introduction: Alcohol use disorder (AUD) is prevalent and recognized as a chronic, relapsing disorder. Even though effective treatment options are available, AUD is strongly undertreated. As adjuvant treatment strategies accompanying psychosocial treatments, pharmacological strategies can increase the efficacy of AUD treatment options.
View Article and Find Full Text PDFEfficacy of sodium oxybate plus disulfiram for the maintenance of alcohol abstinence in treatment-resistant patients with alcohol use disorder: a multicentre retrospective study.
Ann Ist Super Sanita
December 2024
Dipartimento di Medicina Traslazionale e per la Romagna, Università di Ferrara, Ferrara, Italy.
Introduction: Disulfiram (DF), acamprosate, naltrexone, baclofen and sodium oxybate (SO) are currently the medications approved for the treatment of alcohol use disorder (AUD). In this context, combined pharmacological interventions and sex differences are an interesting area in the treatment of non-responder AUD patients.
Aim: To evaluate the efficacy of SO in combination with DF in maintaining alcohol abstinence in patients with AUD who failed to achieve abstinence either with SO or DF alone.
Introduction: Approved treatments for alcohol use disorder by regulatory agencies.
Int Rev Neurobiol
November 2024
Molecular and Behavioral Neuroscience Laboratory, Department of Pharmacology, Universidade Federal de São Paulo (UNIFESP), São Paulo, São Paulo, Brazil. Electronic address:
Alcohol, the most widely consumed substance globally, can lead to severe adverse effects for both users and those around them. Chronic ethanol consumption may lead to alcohol use disorder (AUD), a chronic relapsing condition characterized by compulsive drinking despite negative consequences. AUD is marked by a high relapse rate among individuals attempting abstinence.
View Article and Find Full Text PDFDisparities in Treatment for Alcohol Use Disorder Among All of Us Participants.
Am J Psychiatry
November 2024
Center for Value-Based Care Research, Cleveland Clinic (Le, Rich, Gasoyan, Rothberg) and Department of Pharmacy and Center for Geriatric Medicine, Cleveland Clinic, Cleveland, Ohio (Ayers); Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland (Rich); Department of General Internal Medicine, Massachusetts General Hospital, Boston (Bernstein); Kaiser Permanente Washington Health Research Institute, Seattle (Glass); Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, and Ralph H. Johnson VA Healthcare System, Charleston (Back); TSET Health Promotion Research Center, Stephenson Cancer Center, and Department of Family and Preventive Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City (Bui).
Objective: The authors examined racial/ethnic and socioeconomic disparities in receiving treatment for alcohol use disorder (AUD).
Methods: A retrospective cohort study was conducted that included adults (≥18 years) with AUD from the All of Us Controlled Tier database v7. Outcomes were lifetime receipt of FDA-approved medications (disulfiram, acamprosate, and naltrexone), psychotherapy (individual, family, and group-based session), and combination treatment (medication and psychotherapy).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!